All In Biotech

Drug Trial Radar · NCT04684628

68Ga-PSMA PET/CT in Prostate Cancer

Investigation of the Sensitivity and Specificity of 68Ga-HBED-CC-PSMA PET/CT in Prostate Cancer

Last checked: Nov 19, 2026Latest source record: May 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 9, 2020

Primary completion

Jan 2025

Study completion Dec 2025

Sponsor

Lead sponsor
University of SaskatchewanAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, multi-arm, open-label, phase III trial in up to 500 patients with biopsy-proven prostate cancer. Participants will receive regular standard of clinical care. The only study-specific procedures will the administration of 68Ga-PSMA-11 followed by a PET/CT (positron emission tomography/computed tomography) scan. Participants will be followed for two hours after the infusion for identification of any immediate adverse events (AE), and will be contacted by telephone after 7 to 14 days to enquire about any delayed AEs. PET/CT images, CT-alone images and bone scans will be read by separate readers who will not be blinded to all other clinical and imaging information. The standard of truth will be a consensus of the readers based on all available clinical, imaging, and histopathological information available for up to 6 months after the PET/CT scan.

Conditions

  • Prostate Cancer

Interventions

  • 68Ga-PSMA PET/CTDrug

    Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and specificity of 68Ga-PSMA-11 PET/CT compared to that of CT alone and bone scan in two different cohorts of prostrate cancer patients.Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.